Key takeaways for Utah
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Utah Medicaid coverage rules apply for Prediabetes patients in Utah — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Utah-specific context
Utah has telehealth access concentrated in Salt Lake City, West Valley City, West Jordan metros, with additional reach to Provo and Sandy. University of Utah Health, Intermountain Healthcare is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at medicaid.utah.gov.
Utahtelehealth & pricing rules
- • Utah permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Utah allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Utah: ~$268/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.